سوق خدمات الصحة السلوكية الرقمية العالمية - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTLE

5.2 PORTER

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH NEUROLOGIST

6.8 INTERVIEWS WITH ONCOLOGISTS

6.9 OTHER KOL SNAPSHOTS

7 EPIDEMIOLOGY

7.1 INCIDENCE OF ALL BY GENDER

7.2 TREATMENT RATE

7.3 MORTALITY RATE

7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

7.5 PATEINT TREATMENT SUCCESS RATES

8 REGULATORY & REIMBURSEMENT FRAMEWORK

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DIGITAL THERPEUTICS PIPELINE

9.3 OTHERS (PRE-CLINICAL AND RESEARCH)

10 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 BY USAGE

10.2.1 MEDICATION AUGMENTATION

10.2.2 MEDICATION REPLACEMENT

10.3 BY TYPE

10.3.1 OUTPATIENT TREATMENT

10.3.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

10.3.1.2. FLUENCY TRAINING

10.3.1.3. CONTIGENCY MANAGEMENT

10.3.1.4. CRAVING AND TRIGGER ASSESSMENT

10.3.1.5. TRANSMUCOSAL BUPRENORPHINE

10.3.1.6. OTHERS

10.3.2 MONOTHERAPY

10.3.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

10.3.2.2. COGNITIVE RESTRUCTURING

10.3.2.3. OTHERS

10.3.3 COMBINATION THERAPY

10.3.3.1. SMART WATCH

10.3.3.2. WRISTWATCH/WRISTBAND

10.3.3.3. SMART CLOTHES

10.3.3.4. EAR BANDS

10.3.3.5. OTHERS

10.3.4 OTHERS

11 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY SERVICES

11.1 OVERVIEW

11.2 PHYSICAL ACITIVITY

11.3 RELAXATION TECHNIQUE

11.4 DIET OPTIMIZATION

11.5 CONTROLLED BREATHING

11.6 TELEMEDICINE

11.7 MINDFULNESS TRAINING

11.8 OTHERS

12 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY APP ACCESSIBILITY

12.1 OVERVIEW

12.2 ANDROID

12.2.1 SMARTPHONE

12.2.2 TABLET

12.3 IOS

12.3.1 SMARTPHONE

12.3.2 TABLET

12.4 WINDOWS

12.4.1 SMARTPHONE

12.4.2 TABLET

13 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY APP TYPE

13.1 OVERVIEW

13.2 NATIVE APPS

13.3 WEB APPS

13.4 HYBRID APPS

14 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)

14.2.1 BY USAGE

14.2.1.1. MEDICATION AUGMENTATION

14.2.1.2. MEDICATION REPLACEMENT

14.2.2 BY TYPE

14.2.2.1. OUTPATIENT TREATMENT

14.2.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.2.2.1.2. FLUENCY TRAINING

14.2.2.1.3. CONTIGENCY MANAGEMENT

14.2.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.2.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.2.2.1.6. OTHERS

14.2.2.2. MONOTHERAPY

14.2.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.2.2.2.2. COGNITIVE RESTRUCTURING

14.2.2.2.3. OTHERS

14.2.2.3. COMBINATION THERAPY

14.2.2.3.1. SMART WATCH

14.2.2.3.2. WRISTWATCH/WRISTBAND

14.2.2.3.3. SMART CLOTHES

14.2.2.3.4. EAR BANDS

14.2.2.3.5. OTHERS

14.3 ALZHEIMER’S DISEASE

14.3.1 BY USAGE

14.3.1.1. MEDICATION AUGMENTATION

14.3.1.2. MEDICATION REPLACEMENT

14.3.2 BY TYPE

14.3.2.1. OUTPATIENT TREATMENT

14.3.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.3.2.1.2. FLUENCY TRAINING

14.3.2.1.3. CONTIGENCY MANAGEMENT

14.3.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.3.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.3.2.1.6. OTHERS

14.3.2.2. MONOTHERAPY

14.3.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.3.2.2.2. COGNITIVE RESTRUCTURING

14.3.2.2.3. OTHERS

14.3.2.3. COMBINATION THERAPY

14.3.2.3.1. SMART WATCH

14.3.2.3.2. WRISTWATCH/WRISTBAND

14.3.2.3.3. SMART CLOTHES

14.3.2.3.4. EAR BANDS

14.3.2.3.5. OTHERS

14.3.2.4. OTHERS

14.4 MAJOR DEPRESSIVE DISORDER (MDD)

14.4.1 BY USAGE

14.4.1.1. MEDICATION AUGMENTATION

14.4.1.2. MEDICATION REPLACEMENT

14.4.2 BY TYPE

14.4.2.1. OUTPATIENT TREATMENT

14.4.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.4.2.1.2. FLUENCY TRAINING

14.4.2.1.3. CONTIGENCY MANAGEMENT

14.4.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.4.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.4.2.1.6. OTHERS

14.4.2.2. MONOTHERAPY

14.4.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.4.2.2.2. COGNITIVE RESTRUCTURING

14.4.2.2.3. OTHERS

14.4.2.3. COMBINATION THERAPY

14.4.2.3.1. SMART WATCH

14.4.2.3.2. WRISTWATCH/WRISTBAND

14.4.2.3.3. SMART CLOTHES

14.4.2.3.4. EAR BANDS

14.4.2.3.5. OTHERS

14.4.2.4. OTHERS

14.5 INSOMNIA

14.5.1 BY USAGE

14.5.1.1. MEDICATION AUGMENTATION

14.5.1.2. MEDICATION REPLACEMENT

14.5.2 BY TYPE

14.5.2.1. OUTPATIENT TREATMENT

14.5.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.5.2.1.2. FLUENCY TRAINING

14.5.2.1.3. CONTIGENCY MANAGEMENT

14.5.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.5.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.5.2.1.6. OTHERS

14.5.2.2. MONOTHERAPY

14.5.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.5.2.2.2. COGNITIVE RESTRUCTURING

14.5.2.2.3. OTHERS

14.5.2.3. COMBINATION THERAPY

14.5.2.3.1. SMART WATCH

14.5.2.3.2. WRISTWATCH/WRISTBAND

14.5.2.3.3. SMART CLOTHES

14.5.2.3.4. EAR BANDS

14.5.2.3.5. OTHERS

14.5.2.4. OTHERS

14.6 COGNITION

14.6.1 BY USAGE

14.6.1.1. MEDICATION AUGMENTATION

14.6.1.2. MEDICATION REPLACEMENT

14.6.2 BY TYPE

14.6.2.1. OUTPATIENT TREATMENT

14.6.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.6.2.1.2. FLUENCY TRAINING

14.6.2.1.3. CONTIGENCY MANAGEMENT

14.6.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.6.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.6.2.1.6. OTHERS

14.6.2.2. MONOTHERAPY

14.6.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.6.2.2.2. COGNITIVE RESTRUCTURING

14.6.2.2.3. OTHERS

14.6.2.3. COMBINATION THERAPY

14.6.2.3.1. SMART WATCH

14.6.2.3.2. WRISTWATCH/WRISTBAND

14.6.2.3.3. SMART CLOTHES

14.6.2.3.4. EAR BANDS

14.6.2.3.5. OTHERS

14.6.2.4. OTHERS

14.7 EPILEPSY

14.7.1 BY USAGE

14.7.1.1. MEDICATION AUGMENTATION

14.7.1.2. MEDICATION REPLACEMENT

14.7.2 BY TYPE

14.7.2.1. OUTPATIENT TREATMENT

14.7.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.7.2.1.2. FLUENCY TRAINING

14.7.2.1.3. CONTIGENCY MANAGEMENT

14.7.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.7.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.7.2.1.6. OTHERS

14.7.2.2. MONOTHERAPY

14.7.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.7.2.2.2. COGNITIVE RESTRUCTURING

14.7.2.2.3. OTHERS

14.7.2.3. COMBINATION THERAPY

14.7.2.3.1. SMART WATCH

14.7.2.3.2. WRISTWATCH/WRISTBAND

14.7.2.3.3. SMART CLOTHES

14.7.2.3.4. EAR BANDS

14.7.2.3.5. OTHERS

14.7.2.4. OTHERS

14.8 MOVEMENT DISORDER

14.8.1 BY USAGE

14.8.1.1. MEDICATION AUGMENTATION

14.8.1.2. MEDICATION REPLACEMENT

14.8.2 BY TYPE

14.8.2.1. OUTPATIENT TREATMENT

14.8.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.8.2.1.2. FLUENCY TRAINING

14.8.2.1.3. CONTIGENCY MANAGEMENT

14.8.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.8.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.8.2.1.6. OTHERS

14.8.2.2. MONOTHERAPY

14.8.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.8.2.2.2. COGNITIVE RESTRUCTURING

14.8.2.2.3. OTHERS

14.8.2.3. COMBINATION THERAPY

14.8.2.3.1. SMART WATCH

14.8.2.3.2. WRISTWATCH/WRISTBAND

14.8.2.3.3. SMART CLOTHES

14.8.2.3.4. EAR BANDS

14.8.2.3.5. OTHERS

14.8.2.4. OTHERS

14.9 AUSTISM SPECTRUM DISORDER

14.9.1 BY USAGE

14.9.1.1. MEDICATION AUGMENTATION

14.9.1.2. MEDICATION REPLACEMENT

14.9.2 BY TYPE

14.9.2.1. OUTPATIENT TREATMENT

14.9.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.9.2.1.2. FLUENCY TRAINING

14.9.2.1.3. CONTIGENCY MANAGEMENT

14.9.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.9.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.9.2.1.6. OTHERS

14.9.2.2. MONOTHERAPY

14.9.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.9.2.2.2. COGNITIVE RESTRUCTURING

14.9.2.2.3. OTHERS

14.9.2.3. COMBINATION THERAPY

14.9.2.3.1. SMART WATCH

14.9.2.3.2. WRISTWATCH/WRISTBAND

14.9.2.3.3. SMART CLOTHES

14.9.2.3.4. EAR BANDS

14.9.2.3.5. OTHERS

14.9.2.4. OTHERS

14.1 ONCOLOGY

14.10.1 BY USAGE

14.10.1.1. MEDICATION AUGMENTATION

14.10.1.2. MEDICATION REPLACEMENT

14.10.2 BY TYPE

14.10.2.1. OUTPATIENT TREATMENT

14.10.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)

14.10.2.1.2. FLUENCY TRAINING

14.10.2.1.3. CONTIGENCY MANAGEMENT

14.10.2.1.4. CRAVING AND TRIGGER ASSESSMENT

14.10.2.1.5. TRANSMUCOSAL BUPRENORPHINE

14.10.2.1.6. OTHERS

14.10.2.2. MONOTHERAPY

14.10.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)

14.10.2.2.2. COGNITIVE RESTRUCTURING

14.10.2.2.3. OTHERS

14.10.2.3. COMBINATION THERAPY

14.10.2.3.1. SMART WATCH

14.10.2.3.2. WRISTWATCH/WRISTBAND

14.10.2.3.3. SMART CLOTHES

14.10.2.3.4. EAR BANDS

14.10.2.3.5. OTHERS

14.10.2.4. OTHERS

15 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY PATIENTS

15.1 OVERVIEW

15.2 CHILDREN

15.3 ADULTS

15.4 GERIATRICS

16 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.2 COMPANY SHARE ANALYSIS: EUROPE

16.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16.4 MERGERS & ACQUISITIONS

16.5 NEW PRODUCT DEVELOPMENT & APPROVALS

16.6 EXPANSIONS

16.7 REGULATORY CHANGES

16.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

17 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, BY GEOGRAPHY

17.1 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

17.1.1 NORTH AMERICA

17.1.1.1. U.S.

17.1.1.2. CANADA

17.1.1.3. MEXICO

17.1.2 EUROPE

17.1.2.1. GERMANY

17.1.2.2. FRANCE

17.1.2.3. U.K.

17.1.2.4. HUNGARY

17.1.2.5. LITHUANIA

17.1.2.6. AUSTRIA

17.1.2.7. IRELAND

17.1.2.8. NORWAY

17.1.2.9. POLAND

17.1.2.10. ITALY

17.1.2.11. SPAIN

17.1.2.12. RUSSIA

17.1.2.13. TURKEY

17.1.2.14. NETHERLANDS

17.1.2.15. SWITZERLAND

17.1.2.16. REST OF EUROPE

17.1.3 ASIA-PACIFIC

17.1.3.1. JAPAN

17.1.3.2. CHINA

17.1.3.3. SOUTH KOREA

17.1.3.4. INDIA

17.1.3.5. AUSTRALIA

17.1.3.6. SINGAPORE

17.1.3.7. THAILAND

17.1.3.8. MALAYSIA

17.1.3.9. INDONESIA

17.1.3.10. PHILIPPINES

17.1.3.11. VIETNAM

17.1.3.12. REST OF ASIA-PACIFIC

17.1.4 SOUTH AMERICA

17.1.4.1. BRAZIL

17.1.4.2. ARGENTINA

17.1.4.3. PERU

17.1.4.4. REST OF SOUTH AMERICA

17.1.5 MIDDLE EAST AND AFRICA

17.1.5.1. SOUTH AFRICA

17.1.5.2. SAUDI ARABIA

17.1.5.3. UAE

17.1.5.4. EGYPT

17.1.5.5. KUWAIT

17.1.5.6. ISRAEL

17.1.5.7. REST OF MIDDLE EAST AND AFRICA

17.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

18 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, SWOT AND DBMR ANALYSIS

19 GLOBAL DIGITAL BEHAVIORAL HEALTH SERVICES MARKET, COMPANY PROFILE

19.1 PEAR THERAPEUTICS, INC.

19.1.1 COMPANY OVERVIEW

19.1.2 REVENUE ANALYSIS

19.1.3 GEOGRAPHIC PRESENCE

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPEMENTS

19.2 AKILI INTERACTIVE LABS, INC.

19.2.1 COMPANY OVERVIEW

19.2.2 REVENUE ANALYSIS

19.2.3 GEOGRAPHIC PRESENCE

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPEMENTS

19.3 CLICK THERAPEUTICS, INC.

19.3.1 COMPANY OVERVIEW

19.3.2 REVENUE ANALYSIS

19.3.3 GEOGRAPHIC PRESENCE

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPEMENTS

19.4 BETTER THERAPEUTICS, LLC

19.4.1 COMPANY OVERVIEW

19.4.2 REVENUE ANALYSIS

19.4.3 GEOGRAPHIC PRESENCE

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPEMENTS

19.5 XEALTH

19.5.1 COMPANY OVERVIEW

19.5.2 REVENUE ANALYSIS

19.5.3 GEOGRAPHIC PRESENCE

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPEMENTS

19.6 KAIA HEALTH

19.6.1 COMPANY OVERVIEW

19.6.2 REVENUE ANALYSIS

19.6.3 GEOGRAPHIC PRESENCE

19.6.4 PRODUCT PORTFOLIO

19.6.5 RECENT DEVELOPEMENTS

19.7 OMADA HEALTH, INC.

19.7.1 COMPANY OVERVIEW

19.7.2 REVENUE ANALYSIS

19.7.3 GEOGRAPHIC PRESENCE

19.7.4 PRODUCT PORTFOLIO

19.7.5 RECENT DEVELOPEMENTS

19.8 WELLDOC

19.8.1 COMPANY OVERVIEW

19.8.2 REVENUE ANALYSIS

19.8.3 GEOGRAPHIC PRESENCE

19.8.4 PRODUCT PORTFOLIO

19.8.5 RECENT DEVELOPEMENTS

19.9 VOLUNTIS

19.9.1 COMPANY OVERVIEW

19.9.2 REVENUE ANALYSIS

19.9.3 GEOGRAPHIC PRESENCE

19.9.4 PRODUCT PORTFOLIO

19.9.5 RECENT DEVELOPEMENTS

19.1 SOLERA NETWORK

19.10.1 COMPANY OVERVIEW

19.10.2 REVENUE ANALYSIS

19.10.3 GEOGRAPHIC PRESENCE

19.10.4 PRODUCT PORTFOLIO

19.10.5 RECENT DEVELOPEMENTS

19.11 2MORROW INC.

19.11.1 COMPANY OVERVIEW

19.11.2 REVENUE ANALYSIS

19.11.3 GEOGRAPHIC PRESENCE

19.11.4 PRODUCT PORTFOLIO

19.11.5 RECENT DEVELOPEMENTS

19.12 GAIA

19.12.1 COMPANY OVERVIEW

19.12.2 REVENUE ANALYSIS

19.12.3 GEOGRAPHIC PRESENCE

19.12.4 PRODUCT PORTFOLIO

19.12.5 RECENT DEVELOPEMENTS

19.13 RESMED

19.13.1 COMPANY OVERVIEW

19.13.2 REVENUE ANALYSIS

19.13.3 GEOGRAPHIC PRESENCE

19.13.4 PRODUCT PORTFOLIO

19.13.5 RECENT DEVELOPEMENTS

19.14 DTHERA SCIENCES

19.14.1 COMPANY OVERVIEW

19.14.2 REVENUE ANALYSIS

19.14.3 GEOGRAPHIC PRESENCE

19.14.4 PRODUCT PORTFOLIO

19.14.5 RECENT DEVELOPEMENTS

19.15 SAMSUNG

19.15.1 COMPANY OVERVIEW

19.15.2 REVENUE ANALYSIS

19.15.3 GEOGRAPHIC PRESENCE

19.15.4 PRODUCT PORTFOLIO

19.15.5 RECENT DEVELOPEMENTS

19.16 BIGHEALTH

19.16.1 COMPANY OVERVIEW

19.16.2 REVENUE ANALYSIS

19.16.3 GEOGRAPHIC PRESENCE

19.16.4 PRODUCT PORTFOLIO

19.16.5 RECENT DEVELOPEMENTS

19.17 PROPELLER HEALTH

19.17.1 COMPANY OVERVIEW

19.17.2 REVENUE ANALYSIS

19.17.3 GEOGRAPHIC PRESENCE

19.17.4 PRODUCT PORTFOLIO

19.17.5 RECENT DEVELOPEMENTS

19.18 F. HOFFMANN-LA ROCHE LTD

19.18.1 COMPANY OVERVIEW

19.18.2 REVENUE ANALYSIS

19.18.3 GEOGRAPHIC PRESENCE

19.18.4 PRODUCT PORTFOLIO

19.18.5 RECENT DEVELOPEMENTS

19.19 LIMBIX HEALTH, INC

19.19.1 COMPANY OVERVIEW

19.19.2 REVENUE ANALYSIS

19.19.3 GEOGRAPHIC PRESENCE

19.19.4 PRODUCT PORTFOLIO

19.19.5 RECENT DEVELOPEMENTS

19.2 NUVOAIR AB

19.20.1 COMPANY OVERVIEW

19.20.2 REVENUE ANALYSIS

19.20.3 GEOGRAPHIC PRESENCE

19.20.4 PRODUCT PORTFOLIO

19.20.5 RECENT DEVELOPEMENTS

19.21 ALTRAN

19.21.1 COMPANY OVERVIEW

19.21.2 REVENUE ANALYSIS

19.21.3 GEOGRAPHIC PRESENCE

19.21.4 PRODUCT PORTFOLIO

19.21.5 RECENT DEVELOPEMENTS

19.22 SENSYNE HEALTH PLC

19.22.1 COMPANY OVERVIEW

19.22.2 REVENUE ANALYSIS

19.22.3 GEOGRAPHIC PRESENCE

19.22.4 PRODUCT PORTFOLIO

19.22.5 RECENT DEVELOPEMENTS

19.23 BIOFOURMIS

19.23.1 COMPANY OVERVIEW

19.23.2 REVENUE ANALYSIS

19.23.3 GEOGRAPHIC PRESENCE

19.23.4 PRODUCT PORTFOLIO

19.23.5 RECENT DEVELOPEMENTS

19.24 SMARTPATIENT GMBH

19.24.1 COMPANY OVERVIEW

19.24.2 REVENUE ANALYSIS

19.24.3 GEOGRAPHIC PRESENCE

19.24.4 PRODUCT PORTFOLIO

19.24.5 RECENT DEVELOPMENTS

19.25 BOEHRINGER INGELHEIM

19.25.1 COMPANY OVERVIEW

19.25.2 REVENUE ANALYSIS

19.25.3 GEOGRAPHIC PRESENCE

19.25.4 PRODUCT PORTFOLIO

19.25.5 RECENT DEVELOPMENTS

19.26 BIG HEALTH

19.26.1 COMPANY OVERVIEW

19.26.2 REVENUE ANALYSIS

19.26.3 GEOGRAPHIC PRESENCE

19.26.4 PRODUCT PORTFOLIO

19.26.5 RECENT DEVELOPMENTS

19.27 COGNOA

19.27.1 COMPANY OVERVIEW

19.27.2 REVENUE ANALYSIS

19.27.3 GEOGRAPHIC PRESENCE

19.27.4 PRODUCT PORTFOLIO

19.27.5 RECENT DEVELOPMENTS

19.28 GLOOKO

19.28.1 COMPANY OVERVIEW

19.28.2 REVENUE ANALYSIS

19.28.3 GEOGRAPHIC PRESENCE

19.28.4 PRODUCT PORTFOLIO

19.28.5 RECENT DEVELOPMENTS

19.29 WELLDOC

19.29.1 COMPANY OVERVIEW

19.29.2 REVENUE ANALYSIS

19.29.3 GEOGRAPHIC PRESENCE

19.29.4 PRODUCT PORTFOLIO

19.29.5 RECENT DEVELOPMENTS

19.3 MEDRHYTHMS

19.30.1 COMPANY OVERVIEW

19.30.2 REVENUE ANALYSIS

19.30.3 GEOGRAPHIC PRESENCE

19.30.4 PRODUCT PORTFOLIO

19.30.5 RECENT DEVELOPMENTS

*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

20 RELATED REPORTS

21 CONCLUSION

22 QUESTIONNAIRE

23 ABOUT DATA BRIDGE MARKET RESEARCH